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http:WHAT THIS PAPER ADDS
Percutaneous endovascular aneurysm repair is an attractive approach for aneurysm repair. This possibility has
emerged with the utilization of vessel closure devices such as the Prostar XL device. This study analyzed factors
that inﬂuence the success rate of percutaneous closure using this device in order to improve pre-operative
clinical decision making.Objective: To identify predictors of failure in percutaneous endovascular aneurysm repair (P-EVAR) using the
Prostar XL Percutaneous Vascular Surgery Device (Abbot Vascular, Santa Clara, CA, USA) and the need for
conversion to conventional femoral cutdown (O-EVAR).
Methods: Consecutive patients who underwent P-EVAR with the Prostar XL device between January 2009 and
April 2012 were included in this series. Patients with a circular calciﬁed common femoral artery (CFA) on
computed tomography angiography were operated using O-EVAR and were therefore excluded. To identify
predictors of success of closure in P-EVAR, artery characteristics, sheath size used, and comorbidities were
analyzed in a univariate logistic regression model.
Results: Percutaneous access was achieved in 154 femoral access sites with conversion to O-EVAR was needed in
10 (6.5%). Signiﬁcant predictors of conversion included sheath size (continuous, relative risk [RR] 1.50, p < .03)
and the ratio between sheath size and CFA diameter >0.75 (RR 8.93, p < .01). Variables such as calciﬁcation
quantity scores, CFA diameter, body mass index, and comorbidities were not signiﬁcant.
Conclusion: The data demonstrate that sheath size, in particular, combined with CFA diameter predicts failure of
closure in P-EVAR using the Prostar XL device. This ratio can be utilized to help in decision making with regard to
the EVAR approach. A ratio of >0.75 would favor a primary open groin approach.
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Percutaneous access and closure of the vascular defect for
endovascular aneurysm repair (P-EVAR) has been shown to
be a safe and effective method for endovascular repair of
abdominal aortic aneurysms (AAAs) and thoracic aortic
aneurysms (TAAs).1e4
Evidence suggests that totally percutaneous access to the
common femoral artery (CFA) accelerates patients’ surgical
recovery, reduces length of stay, saves procedural time, and
reduces local post-operative complications compared with
open femoral access (O-EVAR). This might result in
improved safety outcomes and reduced costs.5
The Prostar XL Percutaneous Vascular surgery device
(Abbot Vascular, Santa Clara, CA, USA) is a suture mediatedof original article: http://dx.doi.org/10.1016/j.ejvs.2014.12.005
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//dx.doi.org/10.1016/j.ejvs.2014.10.017arterial closure device. It is a CE Mark approved closure
device for large size femoral artery punctures from 8 to
24 Fr. Although use of the Prostar XL device has proven to
be safe and feasible, some variables may play a role in the
failure of successful vessel closure with it. In a limited
number of studies large sheath size, surgeon experience,
vessel calciﬁcation, groin scarring, vessel diameter, and
obesity have been reported as predictors of failure.3,6e11
In the literature, the average success rate for access
closure with the Prostar XL device is 91% (range 87e95%).5
Depending on the sheath size, some centers advocate the
use of two Prostar XL devices to achieve successful closure.
In most studies, the deﬁnition of success for closing
percutaneous access sites using the Prostar XL device is
adequate hemostasis. The deﬁnition of failure for closing
access sites is the need for conversion to conventional
femoral cutdown to stop bleeding or correct vessel
obstruction.
At the authors’ institution percutaneous closure using the
Prostar XL device is routinely used in EVAR. Only one
closure device is applied to each access site. In evaluating
46 M.P. Rijkée et al.the results with this technique, the authors have seen a
constant rate of failure during the last 4 years. This study
describes the mechanism of failure and aims to determine
predictors of immediate failure of closure using the Prostar
XL device and the need for conversion to conventional
femoral cutdown in P-EVAR.
MATERIALS AND METHODS
Patients
From January 2009 to April 2012, 107 consecutive patients
underwent elective EVAR. Eighty-ﬁve (79.0%) of these pa-
tients underwent P-EVAR (AAAs [n ¼ 70], TAAs [n ¼ 10],
AAA þ TAA [n ¼ 1], common iliac artery [CIA] aneurysms
[n ¼ 2] and CIA-redos [n ¼ 2]) using the Prostar XL device
and were prospectively maintained in a database of the
vascular surgery department of the Haga Hospital, The
Hague, The Netherlands. Imaging data were retrospectively
added to this database. This study was approved by the
local ethical committee of Haga Hospital. Patients with
circumferentially calciﬁed femoral access sites or CFA ste-
noses identiﬁed on computed tomography angiography
(CTA), underwent primary O-EVAR. Patients who were
treated endovascularly for a ruptured AAA were also
excluded from this analysis. On the basis of access site,
further exclusion criteria were CFA aneurysms (n ¼ 1) with
a cut-off size of >20 mm and missing CTA data on the CFA
access site location (n ¼ 1), resulting in a total of 154 P-
EVAR access sites in 84 patients.
Data collected to determine predictors of success
included patient demographics, comorbidities, inner diam-
eter of sheath sizes, and vessel characteristics. In this study,
only Cook (Bloomington, IN, USA) devices were used.
Therefore, the sheath outer diameter was not re-measured.
CFA size was measured in mm, from outer wall to outer
wall, 10 mm proximal from the origin of the profunda
femoris artery using axial cut CTA scan images. The degree
of arterial wall calciﬁcation was measured using CTA and
deﬁned as a percentage of total wall circumference. The
degree of calciﬁcation was then divided into three cate-
gories: grade I (<25%), grade II (<50%), and grade III
(>50% except circumferential calciﬁcations) (Fig. 1). Calci-
ﬁcation location consisted of three groups: none or poste-
rior, scattered anterior, and fully anterior calciﬁcations. AFigure 1. Examples of calciﬁcation scores Iratio between sheath size and CFA size (SA ratio) was
calculated by dividing sheath size by 3 (in order to get
sheath diameter from Fr to mm) and dividing that number
by CFA diameter.
All patients underwent CTA 1 month post-operatively.
After this, a duplex scan or CTA was only performed
when indicated to track complications that could have
originated from the intervention. With a total follow up of 1
year, CFA stenosis, endograft limb occlusion, and CFA false
aneurysms were marked as late complications that might
have originated from the use of the Prostar XL device.Surgical procedure
The surgical procedure was routinely performed in the
operating theatre under general or spinal anesthesia. The
operating team consisted of a vascular surgeon (RvE, JW or
BK) or vascular fellow under the supervision of a vascular
surgeon, and an interventional radiologist (LvD, HvO). The
placement of the Prostar XL device was performed by either
the vascular surgeon or interventional radiologist. One
Prostar XL device per femoral access site was routinely used
independent of the sheath size (9e22 Fr). The CFA was
always punctured under ultrasound guidance to make sure
that it was cannulated. Special attention was paid to
entering the vessel wall above the femoral bifurcation on a
central location on the anterior surface of the vessel wall.
Areas with severe calciﬁcation or the presence of plaque
were avoided. If needed, a more proximal or distal entry
point in the length of the CFA was chosen. After successful
puncture of the femoral artery, a short guidewire and 9-Fr
sheath were introduced. Over this sheath, a soft guide-
wire was introduced and secured in the aorta. After
removal of the sheath, the Prostar XL device was then
introduced over the guidewire. After correct placement of
the Prostar XL device sutures the device was replaced by a
9-Fr sheath and the EVAR procedure was started. No sheath
exchange for limb extensions was needed in any case.
After the EVAR procedure all sheaths were removed and
the percutaneous knots were placed ensuring that
adequate hemostasis was achieved. If necessary, manual
compression was performed for 10 minutes. When there
was inadequate hemostasis after placement of the knots a(0e25%), II (25e50%), and III (>50%).
Table 1. Patient characteristics on an access site basis and success
rate per variable.
Variables Total Success Failure
Age (y) (mean  SD) 74.4  8.04 74.5  8.23 70.6  7.07
Body mass index
(mean  SD)
26.4  3.91 27.6  4.18 27.44  4.16
Female, n (%) 26 (17.0) 24 2
Male, n (%) 128 (83.0) 120 8
Calciﬁcation score, n (%)
I 111 (72.1) 104 7
II 25 (16.2) 25 0
III 18 (11.7) 15 3
Calciﬁcation location, n (%)
Posterior or none 125 (81.2) 117 8
Scattered anterior 22 (14.3) 22 0
Full anterior 7 (4.5) 5 2
Sheath size (Fr), n (%)
18 89 (58.0) 86 3
20 65 (42.0) 58 7
CFA diameter (mm) 10.9  2.03
SA ratio
0.75, n (%) 139 (90.0) 133 6
>0.75, n (%) 15 (10.0) 11 4
Comorbidities, n (%)
Hypertension 110 (71.2) 102 8
IDDM 4 (2.6) 4 0
N-IDDM 34 (22.2) 32 2
Statin use 103 (66.7) 97 5
CAD 65 (42.5) 59 6
Stroke 22 (14.0) 20 2
PAOD 9 (5.2) 9 0
Note. CFA ¼ common femoral artery; SA ratio ¼ ratio between
sheath size and CFA size; IDDM ¼ insulin dependent diabetes;
N-IDDM ¼ non-insulin dependent diabetes; CAD ¼ coronary
artery disease; PAOD ¼ peripheral artery occlusive disease.
Predictors of Failure of Closure in Percutaneous EVAR 47small skin incision was made and the defect in the artery
wall was surgically sutured.Statistical analysis
All analyses were performed on an access site basis. To
identify possible predictors, relative risks for the different
variables were calculated using a univariate logistic regres-
sion. All analysis were performed using SPSS version 21.0
(IBM, Armonk, NY, USA).RESULTS
One hundred and ﬁfty-four access sites in 85 individual P-
EVAR procedures were investigated. The mean patient age
was 74.4  8.0 years, with a mean body mass index (BMI)
of 26.4  3.9. Mean CFA diameter was 10.9 mm  2.03.
Sheath diameter ranged from 14 to 22 Fr (14 Fr, n ¼ 13;
16 Fr, n ¼ 43; 18 Fr, n ¼ 33; 20 Fr, n ¼ 56; 22 Fr, n ¼ 9).
Access site calciﬁcation scores were as follows: 111 (72.1%)
grade I; 25 (16.2%) grade II; 18 (11.7%) grade III. Access site
calciﬁcation location consisted of 125 posterior or no cal-
ciﬁcations (81.2%), 22 scattered anterior (14.3%) and seven
full anterior calciﬁcations (4.5%). The average SA ratio was0.57  0.12. For patient characteristics and success rates,
see Table 1.
In 144 of 154 (93.5%) access sites successful closure was
achieved using a single Prostar XL device. In 10 cases (6.5%)
access sites conversion to femoral cutdown was needed in
order to achieve adequate hemostasis after unsuccessful
placement of Prostar XL device sutures.
Conversion numbers in the different calciﬁcation quantity
score groups I, II, and III were seven (n ¼ 111), zero (n ¼ 25,
relative risk [RR] .00, p ¼ .99), and three (n ¼ 18, RR 2.97;
p ¼ .14), respectively, and, using grade I as a reference, did
not differ signiﬁcantly from each other. Calciﬁcation location
scores were also not signiﬁcant. CFA diameter had no effect
on the rate of conversion (RR .78, p ¼ .13). Three conver-
sions were needed using smaller (18-Fr) sheaths (n ¼ 86)
versus seven conversions using larger (20-Fr) sheaths
(n ¼ 65) and did not reach statistical signiﬁcance (RR 3.52,
p ¼ .08). Continuous statistical analysis for sheath size
proved to be a predictor (RR 1.50, p ¼ .03). The highest
level of signiﬁcance was found comparing SA ratios. An SA
ratio >0.75 (n ¼ 15; 10.0%) showed a much higher con-
version rate of four versus six conversions in the much
larger group with an SA ratio <0.75 (n ¼ 139; 90.0%) (RR
8.93, p < .01). There were no signiﬁcant differences in
conversion rate for age, BMI, sex, or comorbidities such as
hypertension, diabetes (insulin dependent and non-insulin
dependent), statin use, coronary artery disease, stroke, or
peripheral vascular disease (see Table 2).
The present analysis found that conversion was needed for
ruptured arterial access site in two cases. In one case the
guidewire got stuck between Prostar XL sutures. In another
case itwas speculated that the Prostar XL deviceneedles could
not penetrate a highly calciﬁed vessel wall. In all other cases
there was no clear reason why there was not adequate he-
mostasis. All conversions were performed because of inade-
quate hemostasis. No conversions were needed because of
CFA occlusion or stenosis during the procedure. In all cases
there was adequate hemostasis after open surgical repair.
Hospital admission in days was not signiﬁcantly higher in
the group with conversions (7.10  6.72 days) compared
with successful closure (5.19  4.93 days) (p ¼ .27). During
follow up of 1 year, four (2.1%) late complications were
seen. In two cases there was signiﬁcant CFA stenosis, after 1
day and after 4 months respectively, in two different pa-
tients. There was one false aneurysm of the CFA found on
the post-operative CTA after 34 days, which was treated
with an ultrasound guided thrombin injection. In one case,
an occlusion of the endograft limb occurred after 93 days,
although it was believed to be due to heavy kinking of the
endograft. All late complications occurred in access sites
that did not need conversion to O-EVAR.DISCUSSION
The avoidance of a skin incision in the groin is a clearly
attractive option in EVAR. With the availability of closure
devices for larger sheath sizes, some centers have adopted
the percutaneous technique as their routine approach.
Table 2. Univariate analysis for failure of percutaneous
endovascular aneurysm repair.
Variables RR (univariate
analysis)
p (univariate
analysis)
Age (y) .94 .12
Body mass index .99 .87
Femalea
Male .80 .79
Calciﬁcation quantity score
Ia e e
II .00 .99
III 2.97 .14
Calciﬁcation location
Posterior or nonea e e
Scattered anterior .00 .98
Full anterior 5.85 .53
Sheath size (Fr)
Continuous 1.50 .03
18a e e
20 3.52 .08
CFA diameter (mm)
Continuous .78 .13
SA ratio
0.75a e e
>0.75 8.93 <.01
Comorbidities
Hypertension 1.65 .54
IDDM .00 .99
N-IDDM .86 .87
Statin use .49 .27
CAD 2.16 .25
Stroke 1.55 .60
PAOD .00 .99
Note. RR ¼ relative risk; CFA ¼ common femoral artery; SA
ratio ¼ ratio between sheath size and CFA size; IDDM ¼ insulin
dependent diabetes; N-IDDM ¼ non-insulin dependent diabetes;
CAD ¼ coronary artery disease; PAOD ¼ peripheral artery
occlusive disease.
a Variable used as reference.
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feasible in P-EVAR and has been used in the authors’ center
for >3 years. The center’s success rate of 93.5% is in
agreement with previous ﬁndings.5
Looking at the possible factors that cause failure of the
percutaneous technique, the present study proposed two new
possible predictors of conversion to O-EVAR: vessel calciﬁca-
tion scores based on the quantity and location of calciﬁcation,
and an SA ratio based on CFA diameter and sheath size.
In contrast to other studies, no signiﬁcant ﬁndings of
closure failure in smaller sized CFAs were found.11 This
might be due to a large mean CFA diameter in a study group
in which 83% of patients were men.
Multiple studies have revealed a signiﬁcantly higher risk
of conversion using larger sheath sizes.7,8,11e14 Two recent
meta-analyses highlighted this ﬁnding of increasing failure
with a larger sheath size (20 Fr).7,15 The present study in
part conﬁrms this ﬁnding, with an increased RR of 1.50
(p ¼ .03) in a continuous model using larger sheath size.
However, no signiﬁcance was found comparing small
(18 Fr) and large sheath sizes (20 Fr) (RR 3.52, p ¼ .08).Interestingly, combining CFA size and sheath size into a
ratio showed a much higher conversion rate in the group
with high SA ratios. An SA ratio >0.75 was associated with
an 8.93-fold relative increased risk of conversion to O-EVAR
compared with SA ratios <0.75 (p < .01). This might indi-
cate that small CFA size or sheath size alone may not be a
predictor, but that the two combined are. It is not hard to
imagine that sheath size is always relative to CFA size.
Looking at absolute numbers, four of 15 access sites with an
SA ratio >0.75 were converted to O-EVAR compared with
six of 133 with an SA ratio <0.75. It is stated in the man-
ufacturer’s instructions that there are no contraindications
for the use of the Prostar XL device. Based on the ﬁndings
of the present study, a high SA ratio should, in the authors’
opinion, be a contraindication for P-EVAR and therefore
using primary O-EVAR in access sites with an SA ratio >0.75
is recommended. In daily practice, the authors now use this
variable in pre-operative screening. However, more studies
are needed to conﬁrm its value.
BMI was not a predictor of failure, which is in agreement
with a recent meta-analysis by Jaffan et al.15 Our study
population had a relatively low mean BMI of 26.4.With only
eight patients exceeding a BMI of 30, not much can be said
about this particular group.
The precise role of vessel calciﬁcation in preventing
successful closure is unclear. Severe vessel calciﬁcation was
a signiﬁcant predictor of failure of closure in some
studies.6,10 However, the role of vessel calciﬁcation was not
conﬁrmed in other studies.3,9 In an attempt to grade the
degree of CFA calciﬁcation using a calciﬁcation quantity and
location score, the present study did not show any differ-
ence in conversion rate based on vessel wall calciﬁcation
quantity or location. This is in contrast to the ﬁndings of
Mousa et al.10 One explanation for the results of the pre-
sent study may be that although access sites scored high in
calciﬁcation scores, heavily calciﬁed sites were avoided us-
ing ultrasound guidance. Moreover, circumferentially calci-
ﬁed access sites, identiﬁed on preoperative CTA, underwent
primary O-EVAR.
Taken together, the authors recommend evaluation of
the CFA diameter with CTA in relation to the sheath size to
be used, prior to performing P-EVAR. Ultrasound guidance
should be used to avoid heavily calciﬁed areas.
Several limitations of the present study should be
acknowledged. The study was retrospective and affected by
the known limitations regarding data selection; it also
contained a relatively small sample size of 154 access sites.
In most recent studies surgeon experience was a pivotal
predictor of success; this was not taken into account in the
present study.3,6,9,10 A few other predictors, such as groin
scarring and CFA kinking, were also not taken into account.
Better documentation and a fully prospective study design
should eliminate these problems in the future.CONCLUSION
The data presented suggest that the use of The Prostar XL
Percutaneous Vascular surgery device in P-EVAR is safe and
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sites. This is in agreement with other studies. A newly
introduced calciﬁcation quantity and location score system
failed to predict failure. Sheath size proved to be a signiﬁ-
cant predictor of failure (RR 1.50, p ¼ .03). However, large
sheath sizes (20 Fr) did not result in a higher conversion
rate than smaller sheath sizes (18 Fr). A combination of
sheath size and CFA diameter was a signiﬁcant predictor of
failure, with a much higher conversion rate in the group of
patients with an SA ratio>0.75 (RR 8.93, p < .01). Based on
these ﬁndings the authors recommend O-EVAR in access
sites with an SA ratio >0.75 and advise the use ultrasound
guidance in every case of P-EVAR when using the Prostar XL
device. As, to the authors’ knowledge, this is the only study
that has analyzed this SA ratio, further research has to be
done in order to validate this predictor of failure.
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